Prespecified pooled secondary analysis of SELECT, FLOW and SOUL (30 787 participants with CKD or atherosclerotic cardiovascular disease): semaglutide vs placebo reduced a kidney composite including cardiovascular death (973 vs 1134 events; HR 0·84, 0·77–0·91).
Secondary analysisn = 30,787
Mann et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis